Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy.

@article{Ahmed2016ClinicalOO,
  title={Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy.},
  author={Kamran A Ahmed and Dexter G Stallworth and Yoon Kyu Kim and Peter A. S. Johnstone and Louis B. Harrison and Jimmy J. Caudell and Hsin-Hao Yu and Arnold B. Etame and Jeffrey S. Weber and Geoffrey Thomas Gibney},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2016},
  volume={27 3},
  pages={434-41}
}
BACKGROUND The anti-programmed death-1 (anti-PD-1) therapy nivolumab has significant clinical activity in patients with metastatic melanoma. However, little is known about the safety and outcomes in patients receiving anti-PD-1 therapy and stereotactic radiation for the treatment of brain metastases (BMs). PATIENTS AND METHODS Data were analyzed… CONTINUE READING